Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma.

Gremel G, Ryan D, Rafferty M, Lanigan F, Hegarty S, Lavelle M, Murphy I, Unwin L, Joyce C, Faller W, McDermott EW, Sheahan K, Ponten F, Gallagher WM.

Br J Cancer. 2011 Aug 9;105(4):565-74. doi: 10.1038/bjc.2011.249. Epub 2011 Jul 5.

2.

Vitamin D and systemic cancer: is this relevant to malignant melanoma?

Osborne JE, Hutchinson PE.

Br J Dermatol. 2002 Aug;147(2):197-213. Review.

PMID:
12174089
3.

Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation.

Vachtenheim J, Ondrušová L.

Exp Dermatol. 2015 Jul;24(7):481-4. doi: 10.1111/exd.12724. Review.

PMID:
25866058
4.

Y-box binding protein 1--a prognostic marker and target in tumour therapy.

Kosnopfel C, Sinnberg T, Schittek B.

Eur J Cell Biol. 2014 Jan-Feb;93(1-2):61-70. doi: 10.1016/j.ejcb.2013.11.007. Epub 2013 Dec 27. Review.

PMID:
24461929
5.

Desmoplastic melanoma, neurotropism, and neurotrophin receptors--what we know and what we do not.

Frydenlund N, Mahalingam M.

Adv Anat Pathol. 2015 Jul;22(4):227-41. doi: 10.1097/PAP.0000000000000076. Review.

PMID:
26050260
6.

De-regulation of ubiquitin-dependent proteolysis and the pathogenesis of malignant melanoma.

Fuchs SY.

Cancer Metastasis Rev. 2005 Jun;24(2):329-38. Review.

PMID:
15986141

Supplemental Content

Support Center